KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
Jason J. Luke(University of Chicago), Alexander M.M. Eggermont(University Medical Center Utrecht), James R. Anderson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Merrick I. Ross(Johns Hopkins University), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Axel Hauschild(University Hospital Schleswig-Holstein), Georgina V. Long(The University of Sydney), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Andrew Poklepovic(Virginia Commonwealth University), Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), Matteo S. Carlino(The University of Sydney), Richard A. Scolyer(The University of Sydney), Caroline Robert(Institut Gustave Roussy), Sama Ahsan(Merck & Co., Inc., Rahway, NJ, USA (United States)), John M. Kirkwood(UPMC Hillman Cancer Center), Jean-Jacques Grob(Aix-Marseille Université), Charles H. Yoon(Brigham and Women's Hospital)
Cited by 76
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k